CN100522949C - 哌嗪二酮类化合物 - Google Patents

哌嗪二酮类化合物 Download PDF

Info

Publication number
CN100522949C
CN100522949C CNB018125212A CN01812521A CN100522949C CN 100522949 C CN100522949 C CN 100522949C CN B018125212 A CNB018125212 A CN B018125212A CN 01812521 A CN01812521 A CN 01812521A CN 100522949 C CN100522949 C CN 100522949C
Authority
CN
China
Prior art keywords
compound
dione
methylene
piperazine
benzyloxypyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018125212A
Other languages
English (en)
Chinese (zh)
Other versions
CN1441789A (zh
Inventor
邓哲明
王惠珀
艾里克·I·C·李
李昂
顾记华
陈惠婷
范扬彬
陈雅兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
YIFA SCIENCE AND TECHNOLOGY Co Ltd
Original Assignee
YIFA SCIENCE AND TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by YIFA SCIENCE AND TECHNOLOGY Co Ltd filed Critical YIFA SCIENCE AND TECHNOLOGY Co Ltd
Publication of CN1441789A publication Critical patent/CN1441789A/zh
Application granted granted Critical
Publication of CN100522949C publication Critical patent/CN100522949C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Saccharide Compounds (AREA)
  • Devices For Conveying Motion By Means Of Endless Flexible Members (AREA)
CNB018125212A 2000-05-09 2001-05-08 哌嗪二酮类化合物 Expired - Fee Related CN100522949C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30419100P 2000-05-09 2000-05-09
US60/304,191 2000-05-09

Publications (2)

Publication Number Publication Date
CN1441789A CN1441789A (zh) 2003-09-10
CN100522949C true CN100522949C (zh) 2009-08-05

Family

ID=23175471

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018125212A Expired - Fee Related CN100522949C (zh) 2000-05-09 2001-05-08 哌嗪二酮类化合物

Country Status (14)

Country Link
US (1) US6635649B2 (https=)
EP (1) EP1282609B1 (https=)
JP (1) JP5101781B2 (https=)
KR (1) KR100852965B1 (https=)
CN (1) CN100522949C (https=)
AT (1) ATE417614T1 (https=)
BR (1) BR0110745A (https=)
CZ (1) CZ301743B6 (https=)
DE (1) DE60137037D1 (https=)
HU (1) HUP0302358A3 (https=)
NO (1) NO326341B1 (https=)
RU (1) RU2269520C2 (https=)
WO (1) WO2001095858A2 (https=)
ZA (1) ZA200209917B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288545B2 (en) * 2000-05-09 2007-10-30 Angiorx Corporation Piperazinedione compounds
WO2002011676A2 (en) 2000-08-04 2002-02-14 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7935704B2 (en) * 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
NZ539735A (en) * 2002-10-02 2009-07-31 Dmi Biosciences Inc Diagnosis and monitoring of diseases using markers, such as diketopiperazines
EP1622633B1 (en) 2003-05-15 2016-02-24 Ampio Pharmaceuticals, Inc. Treatment of t-cell mediated diseases
US20050192348A1 (en) * 2003-09-25 2005-09-01 David Bar-Or Methods and products which utilize N-acyl-L-aspartic acid
EP1711487A1 (en) * 2004-02-04 2006-10-18 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
EP2300011A4 (en) 2008-05-27 2012-06-20 Dmi Life Sciences Inc THERAPEUTIC PROCESSES AND COMPOUNDS
RU2519948C2 (ru) * 2008-08-22 2014-06-20 Бритиш Коламбиа Кэнсер Эйдженси Бранч Низкомолекулярные ингибиторы n-концевой активации рецептора андрогенов
JP2012524066A (ja) * 2009-04-16 2012-10-11 テリック，インコーポレイテッド チューブリン重合阻害剤としての置換４−アミノ−５−ベンゾイル−２−（フェニルアミノ）チオフェン−３−カルボニトリルおよび置換４−アミノ−５−ベンゾイル−２−（フェニルアミノ）チオフェン−３−カルボキサミド
CA2810844C (en) 2010-09-07 2017-03-21 Dmi Acquisition Corp. Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
US8710062B2 (en) * 2011-03-11 2014-04-29 Taipei Medical University Piperazinedione compounds
SG10201608087WA (en) 2011-10-10 2016-11-29 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
EP3721884A1 (en) 2011-10-10 2020-10-14 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease with da-dkp (= aspartyl-alanyl diketopiperazine)
CN103841974A (zh) 2011-10-28 2014-06-04 安皮奥制药股份有限公司 鼻炎的治疗
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
JP6311097B2 (ja) * 2013-07-31 2018-04-18 学校法人東京薬科大学 微小管脱重合剤
CA2958080A1 (en) 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
CN104356077B (zh) * 2014-09-11 2016-09-14 中国科学院南海海洋研究所 一类不对称酰基保护的2,5-二酮哌嗪衍生物及其制备方法和应用
HK1249051A1 (zh) 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗脑肿瘤的方法
MX383691B (es) 2015-03-06 2025-03-14 Beyondspring Pharmaceuticals Inc Método de tratamiento de cáncer asociado con una mutación de ras.
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
WO2017139231A1 (en) 2016-02-08 2017-08-17 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
RU2760348C2 (ru) 2016-06-06 2021-11-24 Бейондспринг Фармасьютикалс, Инк. Способ уменьшения нейтропении
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
CN109580801B (zh) * 2018-06-26 2021-09-07 深圳海王医药科技研究院有限公司 一种检测微管蛋白抑制剂及相关杂质的高效液相色谱法
CN112010930B (zh) * 2019-05-28 2022-08-02 首都医科大学 Rgd修饰的五环哌嗪二酮及其制备和应用
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
CN117285516A (zh) * 2022-06-16 2023-12-26 大连万众益生大健康有限公司 脱氢苯基阿夕斯汀类化合物、其制备方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940709A (en) * 1984-11-02 1990-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine compound as PAF-antagonist
US5708804A (en) * 1994-07-25 1998-01-13 International Business Machines Corp. Apparatus and method therefor of intelligently searching for information in a personal communications device
US5902812A (en) * 1994-02-14 1999-05-11 Xenova Limited Pharmaceutical piperazine compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5973574A (ja) * 1982-10-21 1984-04-25 Grelan Pharmaceut Co Ltd 環状ジペプチド類
GB8609908D0 (en) * 1986-04-23 1986-05-29 Fujisawa Pharmaceutical Co Piperazine compound
DK181687A (da) * 1986-04-23 1987-10-24 Fujisawa Pharmaceutical Co Piperazinderivater og fremgangsmaade til fremstiling deraf
GB9217331D0 (en) * 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
GB9402807D0 (en) * 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
JP3795093B2 (ja) * 1994-11-25 2006-07-12 キッセイ薬品工業株式会社 １−ヒドロキシインドール誘導体
JP3131574B2 (ja) * 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940709A (en) * 1984-11-02 1990-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine compound as PAF-antagonist
US5902812A (en) * 1994-02-14 1999-05-11 Xenova Limited Pharmaceutical piperazine compounds
US5708804A (en) * 1994-07-25 1998-01-13 International Business Machines Corp. Apparatus and method therefor of intelligently searching for information in a personal communications device

Also Published As

Publication number Publication date
CN1441789A (zh) 2003-09-10
EP1282609A2 (en) 2003-02-12
JP5101781B2 (ja) 2012-12-19
ATE417614T1 (de) 2009-01-15
US20020028819A1 (en) 2002-03-07
BR0110745A (pt) 2003-12-30
WO2001095858A2 (en) 2001-12-20
NO20025373L (no) 2002-12-13
DE60137037D1 (de) 2009-01-29
ZA200209917B (en) 2004-04-28
CZ301743B6 (cs) 2010-06-09
EP1282609A4 (en) 2003-06-04
JP2004510701A (ja) 2004-04-08
US6635649B2 (en) 2003-10-21
NO326341B1 (no) 2008-11-10
RU2269520C2 (ru) 2006-02-10
HUP0302358A2 (hu) 2003-11-28
WO2001095858A3 (en) 2002-03-21
KR100852965B1 (ko) 2008-08-19
CZ20023693A3 (cs) 2003-05-14
NO20025373D0 (no) 2002-11-08
EP1282609B1 (en) 2008-12-17
KR20030005336A (ko) 2003-01-17
HUP0302358A3 (en) 2007-09-28

Similar Documents

Publication Publication Date Title
CN100522949C (zh) 哌嗪二酮类化合物
US8119683B2 (en) Aryl substituted sulfonamide compounds and their use as anticancer agents
KR20010014215A (ko) 항전이활성을 갖는 비스-인돌 유도체, 그의 제조방법 및그를 함유하는 약제학적 조성물
WO2020029980A1 (en) Smad3 inhibitors
EP1741714B1 (en) Heterocyclic compound and anti-malignant-tumor agent containing the same as active ingredient
US11834432B2 (en) Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof
US7288545B2 (en) Piperazinedione compounds
US8710062B2 (en) Piperazinedione compounds
AU2001294505B2 (en) Piperazinedione compounds
CA2408649C (en) Piperazinedione compounds
AU2001294505A1 (en) Piperazinedione compounds
CN115381815B (zh) 独脚金内酯衍生物在制备线粒体自噬抑制剂中的应用
JP2023180347A (ja) ハイブリッド型化合物又はその塩
JP2005507893A (ja) ２０（ｓ）−カンプトテシンの薬学的に許容可能な塩
EP1270008B1 (en) Fused tricyclic analogues of guanosine for treating tumors
CN120192318A (zh) 吡咯里嗪并[2,3-c]喹啉衍生物、合成方法及其应用
WO1998023607A1 (en) 1,4-dihydropyridine derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090805

Termination date: 20120508